Last updated: July 31, 2026
Fluoxymesterone is an established oral androgen with no meaningful late-stage clinical development program, no active innovative-product patent strategy, and limited commercial growth potential. The market is generic, fragmented and driven mainly by continued prescriptions for male hypogonadism, delayed puberty and selected oncology-related indications. Competitive risk comes from testosterone products and other anabolic-androgenic steroids rather than from biosimilars or Paragraph IV litigation.
What is the current clinical-trial status of fluoxymesterone?
Fluoxymesterone has no identified active clinical-development program comparable to a modern branded drug. Current use relies on historical clinical evidence, FDA labeling and post-marketing experience rather than new pivotal trials.
A search of ClinicalTrials.gov records through June 2024 did not identify a recruiting interventional trial in which fluoxymesterone was being developed as the primary investigational product for a new indication.[1] The compound may appear in historical studies, observational research or trials involving androgen therapy, but these records do not establish an active commercial development program.
Which indications are supported by FDA labeling?
The FDA-approved labeling for fluoxymesterone includes:
| Indication |
Current regulatory position |
| Male hypogonadism caused by androgen deficiency |
Approved indication |
| Delayed puberty in males |
Approved indication, with careful assessment of skeletal maturation |
| Palliative treatment of selected advanced breast cancer |
Approved indication in labeling |
| Female-to-male gender transition |
Not a labeled indication for fluoxymesterone |
| Athletic performance or bodybuilding |
Not an approved indication |
Fluoxymesterone is administered orally and is a potent androgen. The product label warns about hepatotoxicity, cholestatic hepatitis, peliosis hepatis, hepatic tumors, lipid changes, edema, virilization and suppression of gonadotropin-dependent testicular function.[2]
Are new clinical trials likely?
New trials are unlikely unless a sponsor develops a differentiated formulation or pursues a narrow orphan, oncology or specialty-care indication. Fluoxymesterone has several disadvantages for contemporary development:
- Oral 17-alpha-alkylated androgen exposure creates liver-safety concerns.
- Testosterone products offer broader clinical familiarity and more delivery options.
- Regulatory pathways for new androgen indications require current safety and efficacy evidence.
- The generic product has limited commercial value to support large randomized trials.
- Modern testosterone replacement markets favor transdermal, injectable, buccal and long-acting delivery systems.
A new fluoxymesterone program would therefore most plausibly involve a reformulated product, a restricted specialty indication or a pharmacokinetic and safety study rather than a broad Phase 3 development program.
What is fluoxymesterone and how is it used clinically?
Fluoxymesterone is a synthetic testosterone derivative, also known as 9-alpha-fluoro-11-beta-hydroxy-17-alpha-methyltestosterone. The historical U.S. brand name is Halotestin. Current U.S. products are generally marketed as generic tablets.
The drug is an androgen receptor agonist. Its 17-alpha-methyl structure permits oral administration but is associated with hepatic toxicity. Fluoxymesterone is substantially more androgenic than many testosterone replacement formulations on a milligram basis, which limits routine use and makes dose selection important.
Common clinical considerations include:
- Monitoring liver function tests.
- Monitoring prostate-specific antigen and prostate symptoms in appropriate male patients.
- Assessing hematocrit and lipid changes.
- Monitoring virilization in female patients.
- Avoiding use in patients with prostate or male breast cancer.
- Assessing premature epiphyseal closure in adolescent patients.
- Reviewing drug interactions involving anticoagulants, corticosteroids and glucose-lowering therapy.
What is the FDA regulatory status of fluoxymesterone?
Fluoxymesterone is an FDA-approved prescription androgen. It is also a Schedule III controlled substance under the federal Controlled Substances Act because of abuse and dependence risks.[3]
The product is regulated as a conventional small-molecule drug rather than a biologic. It does not require a biosimilar pathway. Generic versions may rely on the abbreviated new drug application pathway if they demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.
What is the Orange Book status of fluoxymesterone?
Fluoxymesterone products are generally listed as conventional generic drug products rather than as active, patent-protected branded products. The Orange Book should be checked by product strength, dosage form and current marketing status because listings can change as manufacturers discontinue or reactivate products.[4]
The commercial implications are clear:
- No identified active composition-of-matter patent protects the molecule.
- No identified active branded exclusivity period supports premium pricing.
- Patent-based market blocking is limited.
- Generic entry is already established.
- Any remaining barriers are primarily manufacturing, supply, regulatory-compliance and distribution barriers.
What patents protect fluoxymesterone?
The original patents covering fluoxymesterone are historical and expired. No identified active U.S. patent estate provides meaningful exclusivity for the underlying molecule.
| Patent category |
Current position |
| Composition-of-matter patent |
Historical patents expired |
| Original process patents |
Historical rights expired |
| Tablet formulation patents |
No identified commercially significant active estate |
| Method-of-use patents |
No identified active exclusivity supporting current FDA labeling |
| Pediatric exclusivity |
Not an active commercial barrier |
| Orphan-drug exclusivity |
No identified current fluoxymesterone orphan exclusivity |
| Regulatory exclusivity |
No current innovative-product exclusivity identified |
Are there formulation or manufacturing patents?
A sponsor could seek patents on a new formulation, controlled-release tablet, abuse-deterrent dosage form, combination product or manufacturing process. Such patents would protect only the claimed technology and would not restore exclusivity to conventional immediate-release fluoxymesterone tablets.
The principal manufacturing barrier is technical rather than legal. Production requires control of steroid chemistry, impurity profiles, residual solvents, content uniformity and stability. Manufacturers must also comply with controlled-substance handling requirements and FDA current good manufacturing practice rules.
Are there Paragraph IV challenges or fluoxymesterone patent lawsuits?
No major current Paragraph IV dispute involving fluoxymesterone has been identified in the principal public patent-litigation databases reviewed through June 2024. That result is consistent with the product's generic maturity and the absence of a commercially important active patent estate.
What litigation risks affect generic fluoxymesterone?
The principal litigation risks are conventional generic-drug risks:
- Product-liability claims involving hepatic injury or virilization.
- FDA inspection or manufacturing-compliance actions.
- Controlled-substance recordkeeping violations.
- Trade-distribution disputes.
- Antitrust or pricing claims involving generic supply.
- Litigation over a newly patented formulation, if one is introduced.
Patent litigation would become more likely only if a sponsor launched a differentiated delivery system or secured a narrow method-of-use patent with meaningful sales potential.
How does fluoxymesterone compare with testosterone replacement products?
Fluoxymesterone competes in the androgen market but occupies a narrow segment. Testosterone products have stronger clinical adoption, broader dosage-form coverage and larger commercial infrastructure.
| Attribute |
Fluoxymesterone |
Testosterone products |
| Administration |
Oral tablet |
Injectable, transdermal, buccal, nasal and oral formulations |
| Main use |
Selected androgen deficiency and specialty indications |
Broad testosterone-replacement market |
| Liver risk |
Important because of 17-alpha-alkylation |
Varies by formulation; generally lower with non-17-alpha-alkylated products |
| Generic competition |
Established |
Extensive |
| New-product activity |
Limited |
Active formulation and delivery competition |
| Abuse potential |
High |
High |
| Commercial growth |
Low |
Higher, especially for differentiated delivery systems |
| Patent activity |
Minimal for conventional product |
Ongoing for formulations and delivery devices |
Testosterone undecanoate, testosterone cypionate, testosterone enanthate, transdermal testosterone and oral testosterone formulations generally provide more commercially attractive alternatives. Physicians may also select other androgens based on indication, route, safety profile and patient adherence.
What is the fluoxymesterone market size and revenue exposure?
A reliable standalone global revenue figure is not generally available from public company filings because fluoxymesterone sales are usually aggregated within generic pharmaceutical portfolios. The product is not a material revenue driver for a large multinational pharmaceutical company.
Commercial exposure is concentrated among generic manufacturers, contract manufacturers, wholesalers and specialty distributors. Revenue is affected by:
- Number of active suppliers.
- Tablet strength availability.
- Controlled-substance quotas and distribution controls.
- Hospital and retail purchasing contracts.
- Periodic shortages or discontinuations.
- Prescriber preference for testosterone alternatives.
- Reimbursement and generic substitution.
The product's low unit price limits the commercial value of incremental clinical differentiation. A manufacturer would likely need a premium formulation, reliable supply position or bundled specialty distribution strategy to produce material growth.
What is the five-year market projection?
The base-case outlook is stable to declining volume for conventional immediate-release fluoxymesterone, with low-single-digit annual revenue movement driven mainly by price, supply changes and channel mix rather than prescription expansion.
| Scenario |
Five-year market direction |
Key assumptions |
| Base case |
Flat to modest decline |
Stable generic demand, continued substitution by testosterone products |
| Downside case |
Moderate decline |
Additional supplier entry, formulary pressure, product discontinuations |
| Upside case |
Low growth |
Supply shortage, specialty-indication expansion or premium reformulation |
The addressable market is unlikely to expand materially without a new indication or delivery technology. A reformulated product could create a separate premium segment, but it would face the same androgen-safety scrutiny and competition from newer testosterone products.
What generic entry risks exist for fluoxymesterone?
Generic entry is already the prevailing market condition. The principal risk is therefore not first generic entry but intensified competition among existing suppliers.
What could cause a generic launch or supply disruption?
A new generic launch could reduce prices and increase substitution if an ANDA holder receives approval for an unavailable strength or gains a reliable manufacturing source. Conversely, a manufacturer exit could create a temporary shortage and increase short-term pricing power for remaining suppliers.
Supply risk is higher than patent risk because:
- The market is small.
- Few manufacturers may maintain commercial production.
- Steroid manufacturing requires specialized controls.
- Controlled-substance compliance adds operating cost.
- Low prices can make production economically unattractive.
What licensing deals involve fluoxymesterone?
No major recent licensing transaction centered on fluoxymesterone has been identified in public company disclosures through June 2024. The original Halotestin rights are historical and do not represent a current innovative-product licensing platform.
Potential transaction structures would be more likely to involve:
- Generic product acquisition.
- Regional distribution rights.
- Contract manufacturing.
- Portfolio transfers involving multiple controlled substances.
- Rights to a new fluoxymesterone formulation.
A standalone license for conventional fluoxymesterone tablets would have limited strategic value unless it includes manufacturing capacity, market exclusivity in a territory or a differentiated delivery technology.
How strong is the fluoxymesterone patent estate?
The patent estate is weak for conventional products and has little ability to delay generic competition.
| Patent-strength factor |
Assessment |
| Core molecule protection |
Expired |
| Active U.S. patent barrier |
None identified of material commercial significance |
| Formulation protection |
Limited or absent for conventional tablets |
| Method-of-use protection |
Limited or absent |
| Regulatory exclusivity |
None identified |
| Litigation leverage |
Low |
| Manufacturing know-how |
Moderate operational value |
| Supply-chain control |
Potentially meaningful in a small market |
Manufacturing know-how and supplier reliability may create practical advantages, but those advantages do not equal legally enforceable exclusivity.
What is the likely competitive landscape?
The competitive landscape is divided between fluoxymesterone and alternative androgen therapies.
Direct competitors
Direct competitors include generic fluoxymesterone products marketed by multiple manufacturers, subject to product availability and market withdrawal. Competition is usually based on price, wholesaler access, supply continuity and regulatory compliance.
Therapeutic substitutes
The more important competitors are:
- Testosterone cypionate and testosterone enanthate injections.
- Transdermal testosterone gels and patches.
- Buccal testosterone.
- Oral testosterone undecanoate.
- Other androgenic agents used in specialized oncology or endocrine settings.
Fluoxymesterone retains a niche where oral administration, rapid androgenic activity or historical physician familiarity is valued. It loses share when clinicians prioritize lower hepatic risk, broader testosterone-replacement evidence or modern delivery systems.
Key Takeaways
- Fluoxymesterone has no identified active late-stage clinical-trial program.
- FDA-approved uses include male hypogonadism, delayed puberty and selected advanced breast-cancer treatment.
- The drug is a generic, Schedule III oral androgen with significant hepatic and androgenic safety considerations.
- Original composition and process patents have expired.
- No major current Paragraph IV challenge or patent litigation has been identified.
- No biosimilar risk exists because fluoxymesterone is a conventional small molecule.
- Conventional fluoxymesterone revenue is likely small and commercially fragmented.
- The five-year base-case outlook is flat to modestly declining.
- Supply continuity and manufacturing compliance are more important than patent protection.
- Testosterone formulations are the primary competitive threat.
FAQs
Is fluoxymesterone still approved by the FDA?
Yes. Fluoxymesterone remains an FDA-approved prescription androgen available in generic tablet products, subject to current product availability.
Can fluoxymesterone be used for testosterone replacement therapy?
It can be used for selected androgen-deficiency indications under FDA labeling, but clinicians often prefer testosterone products because they offer more delivery options and may present a more suitable safety profile.
Does fluoxymesterone have a biosimilar competitor?
No. Biosimilars apply to biological products. Fluoxymesterone is a chemically synthesized small-molecule drug and competes through generic-drug pathways.
Is fluoxymesterone a controlled substance?
Yes. In the United States, fluoxymesterone is classified as a Schedule III anabolic steroid under the Controlled Substances Act.
Could a new fluoxymesterone formulation obtain patent protection?
Yes. A novel formulation, delivery system, manufacturing process or specific method of use could qualify for patent protection if it satisfies statutory patentability requirements. Such protection would cover the claimed innovation, not the expired fluoxymesterone molecule itself.
References
-
ClinicalTrials.gov. (2024). Search results for fluoxymesterone clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=fluoxymesterone
-
DailyMed. (n.d.). Fluoxymesterone tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Drug Enforcement Administration. (n.d.). Controlled substances act: Schedule III anabolic steroids. https://www.dea.gov/drug-information/drug-scheduling
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
